A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to stronger immune responses and longer survival. These findings, from a large study led by the University of Helsinki and published in Cancer Discovery, highlight how certain ovarian cancer cells can shape the immune response around them, offering clues that may help refine prognosis and future therapies.
This article was originally published on MedicalXpress.com
